MiMedx Group (MDXG) to Release Earnings on Tuesday

MiMedx Group (NASDAQ:MDXG) is scheduled to be releasing its earnings data after the market closes on Tuesday, April 30th. Analysts expect MiMedx Group to post earnings of $0.04 per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). The company had revenue of $86.83 million for the quarter, compared to analyst estimates of $85.58 million. MiMedx Group had a return on equity of 41.12% and a net margin of 14.49%. On average, analysts expect MiMedx Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Stock Performance

NASDAQ:MDXG opened at $6.27 on Friday. The company has a fifty day moving average of $7.47 and a two-hundred day moving average of $7.56. The stock has a market capitalization of $925.33 million, a PE ratio of 19.59 and a beta of 1.32. The company has a debt-to-equity ratio of 0.34, a quick ratio of 3.11 and a current ratio of 3.57. MiMedx Group has a fifty-two week low of $3.53 and a fifty-two week high of $9.27.

Insiders Place Their Bets

In other MiMedx Group news, CAO William Frank Iv Hulse sold 20,381 shares of MiMedx Group stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total transaction of $162,028.95. Following the transaction, the chief accounting officer now directly owns 479,959 shares of the company’s stock, valued at $3,815,674.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other MiMedx Group news, CAO William Frank Iv Hulse sold 20,381 shares of MiMedx Group stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total transaction of $162,028.95. Following the transaction, the chief accounting officer now directly owns 479,959 shares of the company’s stock, valued at $3,815,674.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Ricci S. Whitlow sold 15,493 shares of MiMedx Group stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $8.07, for a total transaction of $125,028.51. Following the transaction, the chief operating officer now directly owns 416,321 shares in the company, valued at $3,359,710.47. The disclosure for this sale can be found here. Insiders have sold 51,145 shares of company stock valued at $409,378 over the last ninety days. Company insiders own 19.90% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on MDXG shares. Mizuho raised their price target on shares of MiMedx Group from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Lake Street Capital started coverage on shares of MiMedx Group in a research note on Thursday, March 7th. They issued a “buy” rating and a $12.00 price target on the stock. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $12.25.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.